Metabolic model for laboratory control of anti-ischaemic therapy effectiveness: a case study of nicorandil

Scientific relevance. A key anti-ischaemic mechanism of some medicinal products involves their effects on the metabolism of endothelial vasodilators, particularly the synthesis of nitric oxide from arginine and its precursor citrulline.

Aim. The study was aimed to determine whether the plasma time course of guanidine derivatives (arginine precursors) is applicable to laboratory control of anti-ischaemic therapy effectiveness using a single oral dose of nicorandil in patients with coronary heart disease as a case study.

Materials and methods. The authors used high-performance liquid chromatography to determine metabolites. Blood samples for analysis were obtained from 30 patients with angina pectoris (Grade II–III, Canadian Cardiovascular Society) and 30 healthy donors. All the study participants received a single oral dose of 20 mg nicorandil after 10 h of fasting.

Results. At baseline, patients showed significantly higher plasma citrulline levels than donors. However, the elevated levels decreased to the healthy range after nicorandil administration. Plasma arginine levels in patients showed a statistically significant increase following nicorandil administration. Plasma homoarginine levels in patients remained reduced both before and after dosing. Nicorandil did not influence elevated levels of the endogenous nitric oxide synthase inhibitor (asymmetrical dimethylarginine).

Conclusions. In addition to the established mechanisms responsible for altering cell metabolism, nicorandil enhances the contribution of citrulline to arginine resynthesis. It is reasonable to include citrulline and arginine, which are involved in the vasodilator response, in model schemes for laboratory control of the effectiveness of anti-ischaemic therapy.

1. Akchurin RS, Alekyan BG, Aronov DM, Belenkov YuN, Boytsov SA, Boldueva SA, et al. 2020 Clinical practice guidelines for stable coronary artery disease. Russian Journal of Cardiology. 2020;25(11):201–50 (In Russ.). https://doi.org/10.15829/29/1560-4071-2020-4076

2. Tarkin JM, Kaski JC. Vasodilator therapy: nitrates and nicorandil. Cardiovasc Drugs Ther. 2016;30(4):367–78. https://doi.org/10.1007/s10557-016-6668-z

3. Zhloba AA. ADMA as a marker and mediator of endothelial dysfunction progression. Arterial Hypertension. 2007;13(2):119–27 (in Russ.). EDN: LSPEPL

4. Chen GF, Baylis C. In vivo renal arginine release is impaired throughout development of chronic kidney disease. Am J Physiol Renal Physiol. 2010;298(1):F95–102. https://doi.org/10.1152/ajprenal.00487.2009

5. Pillai S, Seebeck P, Fingerhut R, Huang JI, Ming X-F, Yang Z, et al. Kidney mass reduction leads to L-arginine metabolism- dependent blood pressure increase in mice. J Am Heart Assoc. 2018;7(5):e008025. https://doi.org/10.1161/JAHA.117.008025

6. Tsikas D. Homoarginine in health and disease. Curr Opin Clin Nutr Metab Care. 2023;26(1):42–9. https://doi.org/10.1097/MCO.0000000000000889

7. Osowska S, Moinard C, Neveux N, Loï C, Cynober L. Citrulline increases arginine pools and restores nitrogen balance after massive intestinal resection. Gut. 2004;53(12):1781–6. https://doi.org/10.1136/gut.2004.042317

8. Couchet M, Pestour S, Breuillard C, Corne C, Rendu J, Fontaine E, et al. Regulation of citrulline synthesis in human enterocytes: Role of hypoxia and inflammation. Biofactors. 2022;48(1):181–9. https://doi.org/10.1002/biof.1810

9. Martsevich SYu, Lukina YuV, Kutishenko NP, Voronina VP, Dmitrieva NA, Zagrebelnyy AV, et al. The first results of the evaluation of long-term nicorandil treatment effect on the probability of cardiovascular complications in patients with stable coronary artery disease (data of observational NIKEA study). Rational Pharmacotherapy in Cardiology 2019;15(3):335–42 (In Russ.). https://doi.org/10.20996/1819-6446-2019-15-3-335-342

10. Zhao XT, Zhang CF, Liu QJ. Meta-analysis of nicorandil effectiveness on myocardial protection after percutaneous coronary intervention. BMC Cardiovasc Disord. 2019;19(1):144. https://doi.org/10.1186/s12872-019-1071-x

11. Zhou J, Xu J, Cheng A, Li P, Chen B, Sun S. Effect of nicorandil treatment adjunctive to percutaneous coronary intervention in patients with acute myocardial infarction: a systematic review and meta-analysis. J Int Med Res. 2020;48(11):300060520967856. https://doi.org/10.1177/0300060520967856

12. Kudaev YuA, Subbotina TF, Lokhovinina NL, Alugishvili MZ, Abesadze IT, Titenkov IV, et al. Prevention of cardiac complications in patients with coronary artery disease undergoing vascular surgery: possibilities of nicorandil. Cardiology and Cardiovascular Surgery. 2022;15(4):402–11 (In Russ.). https://doi.org/10.17116/kardio202215041402

13. Zhloba AA, Subbotina TF, Shipaeva KA. The way for determining the content of homoarginine in blood plasma and other biological fluids of human. Patent of the Russian Federation No. 2609873; 2017 (In Russ.).

14. Zhloba AA, Subbotina TF, Alekseevskaya ES. The content of nitric oxide in blood plasma of health persons depending on age. Russian Clinical Laboratory Diagnostics. 2016;61(11):760–5 (In Russ.). EDN: XHCYQH

15. van de Poll MC, Ligthart-Melis GC, Boelens PG, Deutz NE, van Leeuwen PA, Dejong CH. Intestinal and hepatic metabolism of glutamine and citrulline in humans. J Physiol. 2007;581(Pt 2):819–27. https://doi.org/10.1113/jphysiol.2006.126029

16. Du X, Ma Z, Li L, Zhong X. Nicorandil decreases renal injury in patients with coronary heart disease complicated with type I cardiorenal syndrome. J Cardiovasc Pharmacol. 2021;78(5):e675–80. https://doi.org/10.1097/FJC.0000000000001117

17. Maric S, Restin T, Muff JL, Camargo SM, Guglielmetti LC, Holland-Cunz SG, et al. Citrulline, biomarker of enterocyte functional mass and dietary supplement. Metabolism, transport, and current evidence for clinical use. Nutrients. 2021;13(8):2794. https://doi.org/10.3390/nu13082794